المؤلفون: Madalina Elena Carter-Timofte (11575745), Rozanne Arulanandam (3459344), Naziia Kurmasheva (11575748), Kathy Fu (11575751), Geneviève Laroche (11575754), Zaid Taha (11575757), Demi van der Horst (11575760), Lena Cassin (11575763), Renée M. van der Sluis (11575766), Enrico Palermo (11575769), Daniele Di Carlo (4227652), David Jacobs (74356), Glib Maznyi (11575772), Taha Azad (11210289), Ragunath Singaravelu (425834), Fanghui Ren (782989), Anne Louise Hansen (11575775), Manja Idorn (770510), Christian K. Holm (11575778), Martin R. Jakobsen (8506422), Julien van Grevenynghe (676718), John Hiscott (159374), Søren R. Paludan (8157648), John C. Bell (206340), Jean Seguin (11575781), Luc A. Sabourin (89015), Marceline Côté (1993186), Jean-Simon Diallo (233878), Tommy Alain (414354), David Olagnier (205583)

مصطلحات موضوعية: Biochemistry, Medicine, Pharmacology, Biotechnology, Immunology, Cancer, Mental Health, Infectious Diseases, Virology, mediated membrane fusion, human lung calu, following anecdotal evidence, 3 epithelial cells, potent antiviral fda, full antiviral activity, atovaquone may present, atovaquone administered alone, active compound atovaquone, atovaquone antiviral activity, two clinical trials, antimicrobial medication malarone, antimicrobial drug atovaquone, cov ‑ 2, antiviral potential, atovaquone retained, viral receptor, united states, uncomplicated malaria, treating children, preventing malaria

Relation: https://figshare.com/articles/journal_contribution/Antiviral_Potential_of_the_Antimicrobial_Drug_Atovaquone_against_SARS-CoV_2_and_Emerging_Variants_of_Concern/16825808

الاتاحة: https://doi.org/10.1021/acsinfecdis.1c00278.s001